Skip to main content Accessibility help
×
Hostname: page-component-cb9f654ff-plnhv Total loading time: 0.001 Render date: 2025-08-30T06:25:01.861Z Has data issue: false hasContentIssue false

Chapter 7 - Cannabinoids and Neuropsychiatry

from Section 2 - Potential Therapeutic Uses of Cannabinoids in Clinical Practice

Published online by Cambridge University Press:  12 October 2020

Steven James
Steven James
Affiliation:
University of California, San Diego
Get access

Summary

Jacques-Joseph Moreau was a French psychiatrist in the nineteenth century and an early contributor to the field of psychopharmacology. During a trip in the 1830s to Egypt to study medical customs in the Middle East, Moreau was introduced to hashish, a dried resin from the marijuana flower, as a treatment for both physical and behavioral ailments.

Information

Type
Chapter
Information
A Clinician's Guide to Cannabinoid Science , pp. 86 - 99
Publisher: Cambridge University Press
Print publication year: 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Aguiar, D. C. et al. (2009) ‘Anxiolytic-like effects induced by blockade of transient receptor potential vanilloid type 1 (TRPV1) channels in the medial prefrontal cortex of rats’, Psychopharmacology, 205(2), 217–225. doi:10.1007/s00213-009-1532-5.CrossRefGoogle ScholarPubMed
Aimone, J. B., Deng, W. and Gage, F. H. (2010) ‘Adult neurogenesis: integrating theories and separating functions’, Trends in Cognitive Sciences, 14(7), pp. 325–337. doi:10.1016/j.tics.2010.04.003.Google Scholar
Bedse, G. et al. (2018) ‘Therapeutic endocannabinoid augmentation for mood and anxiety disorders: comparative profiling of FAAH, MAGL and dual inhibitors’, Translational Psychiatry, 8(1). doi:10.1038/s41398-018-0141-7.Google Scholar
Bergamaschi, M. M. et al. (2011) ‘Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients’, Neuropsychopharmacology, 36, 1219–1226. doi:10.1038/npp.2011.6.Google Scholar
Bluett, R. J. et al. (2014) ‘Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation’, Translational Psychiatry, 4, e408. doi:10.1038/tp.2014.53.Google Scholar
Campos, A. C. et al. (2017) ‘Plastic and neuroprotective mechanisms involved in the therapeutic effects of cannabidiol in psychiatric disorders, Frontiers in Pharmacology, 8, 269. doi:10.3389/fphar.2017.00269.CrossRefGoogle ScholarPubMed
Ceccarini, J. et al. (2013) ‘Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia’, NeuroImage, 79, 304–312. doi:10.1016/j.neuroimage.2013.04.052.Google Scholar
Christensen, R. et al. (2007) ‘Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials’, The Lancet, 370(9600), 1706–1713. doi:10.1016/S0140-6736(07)61721-8.Google Scholar
Colucci-D’Amato, L., Bonavita, V. and di Porzio, U. (2006) ‘The end of the central dogma of neurobiology: stem cells and neurogenesis in adult CNS, Neurological Sciences, 27, 266–270. doi:10.1007/s10072-006-0682-z.Google Scholar
Crippa, J. A. et al. (2003) ‘Effects of cannabidiol (CBD) on regional cerebral blood flow’, Neuropsychopharmacology, 29(2), 417–426. doi:10.1038/sj.npp.1300340.Google Scholar
Di Forti, M. et al. (2019) ‘High-potency cannabis and incident psychosis: correcting the causal assumption – authors’ reply’, The Lancet Psychiatry, 6(6), 466–467. doi:10.1016/S2215-0366(19)30176-2.Google Scholar
Dubreucq, S. et al. (2012) ‘Genetic dissection of the role of cannabinoid type-1 receptors in the emotional consequences of repeated social stress in mice’, Neuropsychopharmacology, 37(8), 1885–1900. doi:10.1038/npp.2012.36.Google Scholar
Fay, T. (1941) ‘Observations on prolonged human refrigeration’, Anesthesiology, 2(5), 347–348.Google Scholar
Gage, F. H. (2000) ‘Mammalian neural stem cells’, Science, 287(5457), 1433–1438. doi:10.1126/science.287.5457.1433.CrossRefGoogle ScholarPubMed
Gallily, R., Breuer, A. and Mechoulam, R. (2000) ‘2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-α production in murine macrophages, and in mice’, European Journal of Pharmacology, 406, R5–R7. doi:10.1016/s0014-2999(00)00653-1.Google Scholar
García-Arencibia, M. et al. (2007) ‘Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson’s disease: importance of antioxidant and cannabinoid receptor-independent properties’, Brain Research, 1134(1), 162–170. doi:10.1016/j.brainres.2006.11.063.Google Scholar
Gee, D. G. et al. (2016) ‘Individual differences in frontolimbic circuitry and anxiety emerge with adolescent changes in endocannabinoid signaling across species’, Proceedings of the National Academy of Sciences of the United States of America, 113(16), 4500–4505. doi:10.1073/pnas.1600013113.CrossRefGoogle ScholarPubMed
Ghabrash, M. F. et al. (2020) ‘Cannabidiol for the treatment of psychosis among patients with schizophrenia and other primary psychotic disorders: a systematic review with a risk of bias assessment’, Psychiatry Research, 286, 112890. doi:10.1016/j.psychres.2020.112890.CrossRefGoogle ScholarPubMed
Giuffrida, A. et al. (2004) ‘Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms’, Neuropsychopharmacology, 29(11), 2108–2114. doi:10.1038/sj.npp.1300558.CrossRefGoogle ScholarPubMed
Gobbi, G. et al. (2005) ‘Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis’, Proceedings of the National Academy of Sciences of the United States of America, 102(51), 18620–18625. doi:10.1073/pnas.0509591102.Google Scholar
Gorzalka, B. B. and Hill, M. N. (2011) ‘Putative role of endocannabinoid signaling in the etiology of depression and actions of antidepressants’, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 35(7), 1575–1585. doi:10.1016/j.pnpbp.2010.11.021.CrossRefGoogle ScholarPubMed
Hill, M. N. et al. (2013) ‘Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the world trade center attacks’, Psychoneuroendocrinology, 38(12), 2952–2961. doi:10.1016/j.psyneuen.2013.08.004.Google Scholar
Hill, M. N. and Gorzalka, B. B. (2009) ‘Impairments in endocannabinoid signaling and depressive illness’, JAMA: Journal of the American Medical Association, 301(11), 1165–1166. doi:10.1001/jama.2009.369.Google Scholar
Hindley, G. et al. (2020) ‘Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis’, The Lancet Psychiatry, 7(4), 344–353. doi:10.1016/S2215-0366(20)30074-2.Google Scholar
Hine, R. and Das, G. D. (1974) ‘Neuroembryogenesis in the hippocampal formation of the rat’, Zeitschrift für Anatomie und Entwicklungsgeschichte, 144, 173–186. doi:10.1007/BF00519773.Google Scholar
Horder, J. et al. (2010) ‘Reduced neural response to reward following 7 days treatment with the cannabinoid CB 1 antagonist rimonabant in healthy volunteers’, International Journal of Neuropsychopharmacology, 13(8), 1103–1113. doi:10.1017/S1461145710000453.CrossRefGoogle ScholarPubMed
Hungund, B. L. et al. (2004) ‘Upregulation of CB1 receptors and agonist-stimulated [35S]GTPγS binding in the prefrontal cortex of depressed suicide victims’, Molecular Psychiatry, 9(2), 184–190. doi:10.1038/sj.mp.4001376.Google Scholar
Jacob, W. et al. (2009) ‘Endocannabinoids render exploratory behaviour largely independent of the test aversiveness: role of glutamatergic transmission’, Genes, Brain and Behavior, 8(7), 685–698. doi:10.1111/j.1601-183X.2009.00512.x.Google Scholar
Jain, K. K. (2011) The Handbook of Neuroprotection. New York: Humana Press. doi:10.1007/978-1-61779-049-2.Google Scholar
Kathuria, S. et al. (2003) ‘Modulation of anxiety through blockade of anandamide hydrolysis’, Nature Medicine, 9(1), 76–81. doi:10.1038/nm803.Google Scholar
Klein, D. F. (2008) ‘The loss of serendipity in psychopharmacology’, JAMA: Journal of the American Medical Association, 299(9), 1063–1065. doi:10.1001/jama.299.9.1063.Google Scholar
Kreutz, S. et al. (2009) ‘2-Arachidonoylglycerol elicits neuroprotective effects on excitotoxically lesioned dentate gyrus granule cells via abnormal-cannabidiol-sensitive receptors on microglial cells’, Glia, 57(3), 286–294. doi:10.1002/glia.20756.Google Scholar
Leweke, F. M. et al. (1999) ‘Elevated endogenous cannabinoids in schizophrenia’, NeuroReport, 10(8), 1665–1669. doi:10.1097/00001756-199906030-00008.Google Scholar
Magid, L. et al. (2019) ‘Role of CB2 receptor in the recovery of mice after traumatic brain injury’, Journal of Neurotrauma, 36(11), 1836–1846. doi:10.1089/neu.2018.6063.CrossRefGoogle ScholarPubMed
McGuire, P. et al. (2018) ‘Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial’, American Journal of Psychiatry, 175(3), 197–198. doi:10.1176/appi.ajp.2017.17030325.CrossRefGoogle ScholarPubMed
Mechoulam, R. et al. (2014) ‘Early phytocannabinoid chemistry to endocannabinoids and beyond’, Nature Reviews Neuroscience, 15(11), 757–764. doi:10.1038/nrn3811.CrossRefGoogle ScholarPubMed
Mendelson, W. B. and Basile, A. S. (2001) ‘The hypnotic actions of the fatty acid amide, oleamide’, Neuropsychopharmacology, 25(5), S36–S39. doi:10.1016/S0893-133X(01)00341-4.Google Scholar
Minichino, A. et al. (2019) ‘Measuring disturbance of the endocannabinoid system in psychosis: a systematic review and meta-analysis’, JAMA Psychiatry, 76(9), 914–923. doi:10.1001/jamapsychiatry.2019.0970.Google Scholar
Moreira, F. A. et al. (2008) ‘Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors’, Neuropharmacology, 54(1), 141–150. doi:10.1016/j.neuropharm.2007.07.005.Google Scholar
Moreira, F. A. et al. (2012) ‘Cannabinoid type 1 receptors and transient receptor potential vanilloid type 1 channels in fear and anxiety-two sides of one coin?’, Neuroscience, 204, 186–192. doi:10.1016/j.neuroscience.2011.08.046.Google Scholar
Muguruza, C. et al. (2019) ‘Endocannabinoid system imbalance in the postmortem prefrontal cortex of subjects with schizophrenia’, Journal of Psychopharmacology, 33(9), 1132–1140. doi:10.1177/0269881119857205.Google Scholar
Murphy, L. (2006) ‘Endocannabinoids and endocrine function’, in Onaivi, E. S., Sugiura, T and Di Marzo, V (eds.) Endocannabinoids: The Brain and Body’s Marijuana and Beyond. Boca Raton: CRC Press. pp. 467–474.Google Scholar
Nissen, S. E. et al. (2008) ‘Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: The STRADIVARIUS randomized controlled trial’, JAMA: Journal of the American Medical Association, 299(13), 1547–1560.Google Scholar
O’Brien, L. D. et al. (2013) ‘Effect of chronic exposure to rimonabant and phytocannabinoids on anxiety-like behavior and saccharin palatability’, Pharmacology Biochemistry and Behavior, 103(3), 597–602. doi:10.1016/j.pbb.2012.10.008.Google Scholar
Ortega-Alvaro, A. et al. (2011) ‘Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice’, Neuropsychopharmacology, 36(7), 1489–1504. doi:10.1038/npp.2011.34.Google Scholar
Panikashvili, D. et al. (2001) ‘An endogenous cannabinoid (2-AG) is neuroprotective after brain injury’, Nature, 413(6855), 527–531. doi:10.1038/35097089.Google Scholar
Pinto, J. V. et al. (2020) ‘Cannabidiol as a treatment for mood disorders: a systematic review’, Canadian Journal of Psychiatry, 65(4), 213–217. doi:10.1177/0706743719895195.Google Scholar
Rey, A. A. et al. (2012) ‘Biphasic effects of cannabinoids in anxiety responses: CB1 and GABAB receptors in the balance of GABAergic and glutamatergic neurotransmission’, Neuropsychopharmacology, 37(12), 2624–2634. doi:10.1038/npp.2012.123.Google Scholar
Rubino, T. et al. (2008) ‘CB1 receptor stimulation in specific brain areas differently modulate anxiety-related behaviour’, Neuropharmacology, 54(1), 151–160. doi:10.1016/j.neuropharm.2007.06.024.Google Scholar
Rubino, T., Zamberletti, E. and Parolaro, D. (2015) ‘Endocannabinoids and mental disorders’, in Pertwee, R. G. (ed.), Endocannabinoids. Springer International, pp. 261–283. doi:10.1007/978-3-319-20825-1_9.Google Scholar
Sagredo, O. et al. (2007) ‘Cannabinoids and neuroprotection in basal ganglia disorders’, Molecular Neurobiology, 36(1), 82–91. doi:10.1007/s12035-007-0004-3.Google Scholar
Urigüen, L. et al. (2004) ‘Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors’, Neuropharmacology, 46(7), 966–973. doi:10.1016/j.neuropharm.2004.01.003.Google Scholar
Urigüen, L. et al. (2009) ‘Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment’, Psychopharmacology, 206(2), 313–324. doi:10.1007/s00213-009-1608-2.Google Scholar
Vadodaria, K. C. and Gage, F. H. (2014) ‘SnapShot: adult hippocampal neurogenesis’, Cell, 156(5), 1114–1114.e1. doi:10.1016/j.cell.2014.02.029.Google Scholar
van Os, J. et al. (2002) ‘Cannabis use and psychosis: a longitudinal population-based study’, American Journal of Epidemiology, 156(4), 319–327. doi:10.1093/aje/kwf043.Google Scholar
Viveros, M. P., Marco, E. M. and File, S. E. (2005) ‘Endocannabinoid system and stress and anxiety responses’, Pharmacology Biochemistry and Behavior, 81(2), 331–342. doi:10.1016/j.pbb.2005.01.029.Google Scholar
Zamberletti, E., Rubino, T. and Parolaro, D. (2012) ‘The endocannabinoid system and schizophrenia: integration of evidence’, Current Pharmaceutical Design, 18(32), 4980–4990. doi:10.2174/138161212802884744.Google Scholar
Zhang, X. et al. (2010) ‘Endocannabinoid-like N-arachidonoyl serine is a novel pro-angiogenic mediator’, British Journal of Pharmacology, 160(7), 1583–1594. doi:10.1111/j.1476-5381.2010.00841.x.Google Scholar
Zhao, C., Deng, W. and Gage, F. H. (2008) ‘Mechanisms and functional implications of adult neurogenesis’, Cell, 132(4), 645–660. doi:10.1016/j.cell.2008.01.033.Google Scholar
Zuardi, A. W. et al. (1993) ‘Effects of ipsapirone and cannabidiol on human experimental anxiety’, Journal of Psychopharmacology, 7(1_suppl), 82–88. doi:10.1177/026988119300700112.Google Scholar
Zuardi, A. W. et al. (1995) ‘Antipsychotic effect of cannabidiol’, Journal of Clinical Psychiatry, 56(10), 485–486.Google Scholar

Accessibility standard: Unknown

Accessibility compliance for the PDF of this book is currently unknown and may be updated in the future.

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge-org.demo.remotlog.com is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Cannabinoids and Neuropsychiatry
  • Steven James, University of California, San Diego
  • Book: A Clinician's Guide to Cannabinoid Science
  • Online publication: 12 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781108583336.008
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Cannabinoids and Neuropsychiatry
  • Steven James, University of California, San Diego
  • Book: A Clinician's Guide to Cannabinoid Science
  • Online publication: 12 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781108583336.008
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Cannabinoids and Neuropsychiatry
  • Steven James, University of California, San Diego
  • Book: A Clinician's Guide to Cannabinoid Science
  • Online publication: 12 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781108583336.008
Available formats
×